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Intradermal injection of pruritogens such as serotonin, histamine and compound 48/80 into the skin and then, the evaluation of the 
scratching behavior is the commonly used animal model to advance pruritic research and drug development. However, predictive 
validity of this model is poorly documented. There is a close interaction between itch and pain sensations with regard to mediation 
through an anatomically and functionally identical neuronal pathway. One approach is whether the existing animal model of itch 
differentiates itch or pain to show efficacy of clinically effective analgesic drugs as a back translation. In this study, we explored the 
effects of different group of analgesic drugs on serotonin and compound 48/80-induced scratching behavior in Balb-C mice. Serotonin 
(25 μg) and compound 48/80 (100 μg) was injected intradermally in a volume of 50 μl into the rostral part of skin on the back of male 
mice and scratches were counted for a 30-min observation period. Morphine (1, 3, 10 mg/kg), tramadol (20, 40, 80 mg/kg), cannabinoid 
agonist CP 55,940 (0.1, 0.3, 1 mg/kg), paracetamol (100, 200, 300 mg/kg) and diclofenac (50, 100, 200 mg/kg) were given intraperitoneally 
30 min prior to pruritogen injection. The analgesic drugs dose dependently blocked serotonin and compound 48/80-induced straching 
behavior with exerting complete inhibition at certain doses. Our data suggests that intradermal pruritogen-induced scratching models 
may not discriminate pain and itch sensations and give false positive results when standard analgesic drugs are used.
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INTRODUCTION 
Itch, an unpleasant sensation associated with the desire 
to scratch, is a common symptom of many diseases, including 
those affecting the skin as well as other organ systems. In 
recent years, pruritus has been gained more increased 
interest in medicine due to its higher prevalence than 
thought, serious impact on quality of life such as impaired 
sleep quality, more depressive symptoms and higher levels 
of anxiety (Zachariae et al. 2012) and limited efficacy of 
current antipruritic agents (Carstens and Akiyama 2014). 
The tremendous advances have been made to understand 
the molecular and cellular mechanisms in the transmission 
of itch sensation from periphery to central nervous system 
(Han and Dong 2014). Animal models of itch served as the 
major tool in these advances, from identification of novel 
targets and mechanisms of new therapeutics (Shimada and 
LaMotte 2008, LaMotte et al. 2011). It is well known that 
animal models relevant to human disease or symptom of 
disease is essential for the development of new therapeutics 
and innovative ways to treat and cure the diseases (Denayer 
et al. 2014). Thus, an animal model of itch must fulfill 
some criteria of validity such as predictive validity which 
refers to how specific and sensitive the model is to detect 
pharmacological effects, avoiding false positive or false 
negative results (Gobira et al. 2013).
Although pain and itch are clearly different protective 
sensation, there is a close interaction between them in respect 
of mediation through an anatomically and functionally 
identical neuronal pathway (Davidson and Giesler 2010, © 
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Ringkamp and Meyer 2014). An ideal animal model of itch 
should discriminate pain and itch. Behaviorally, in contrast to 
withdrawal reflex to painful stimuli, the most characteristic 
responses to pruritic stimuli is scratching reflexes (Paus et 
al. 2006). While the significant progress has been performed 
in the development of animal models for itch by changing 
from acute injection models to a disease-relevant approach, 
intradermal injection of pruritogens such as serotonin, 
histamine and compound 48/80 into skin and then, the 
evaluation of the scratching behavior are still the most 
commonly used animal model in research and development 
of pruritus (Akiyama et al. 2010, Kremer et al. 2010, LaMotte 
et al. 2011). Several criticism have been raised against the 
hindlimb scratching behavior as an only indicator of the 
sensation of itch after pruritic stimuli applied to the nape of 
the neck in these standard animal models of itch (Shimada 
and LaMotte 2008, Hachisuka and Ross 2014). One approach 
is whether the existing animal model of itch differentiates 
itch or pain to show efficacy of clinically effective analgesic 
drugs as a back translation. Due to our knowledge, there 
are no comprehensive researches, including multiple dose 
response studies to evaluate effects of analgesic drugs on the 
scratching behaviors of intradermally injected pruritogens 
into the nape of the neck. In this study, we aimed to explore 
the dose response effects of opioid analgesics morphine 
and tramadol, a mixed cannabinoid CB1 and CB2 receptor 
agonist CP 55, 940, paracetamol and diclofenac sodium, 
the nonsteroidal anti-inflammatory drugs (NSAIDs), on 
intradermal compound 48/80 and serotonin induced 
scratching behavior in mice. 
MATERIALS AND METHODS
Animals
Approximately, 6 weeks old male Balb-C mice (23–28 g) 
were used. They were housed in groups of six under controlled 
temperature (22±1°C) and humidity (55±10%). The room 
was lighted from 7:00 a.m. to 7:00 p.m. Food and water were 
available ad libitum. The animals were randomly divided. The 
study was approved by the Committee for Animal Experiments 
of Ondokuz Mayıs University and Gülhane Military Medical 
Academy. 
Drugs and chemicals 
Serotonin hydrochloride (Sigma-Aldrich, St Louis, MO, 
USA) and compound 48/80 (Sigma-Aldrich, St Louis, MO, 
USA) were dissolved in 0.9% saline. Paracetamol and CP 
55,940 (Sigma-Aldrich, St Louis, MO, USA; respectively) were 
dissolved in a vehicle solution containing 20:1:1:78 (v/v/v/v) 
mixture of DMSO:ethanol:Tween 80:0.9% saline. Diclofenac 
sodium (Sigma-Aldrich Co., USA) and morphine sulphate 
(Galen, Istanbul, Turkey) were dissolved in 0.9% saline. 
Tramadol (Contromal amp, 100 mg/kg, Abdi İbrahim, Turkey) 
was diluted in 0.9% saline. All drugs were given into the mice 
by an intraperitoneal (i.p.) route in a volume of 10 ml/kg. 
Behavioral experiments
Serotonin (25 µg) and compound 48/80 (100 µg/site) 
were injected intradermally in a volume of 50 µl into the 
neck, rostral part of the mice. After injections, the animals 
were put in a plexiglass cylinder (20×20×40 cm) and one 
observer calculated the animal behaviour movements only 
for 30 minutes in this area. The scratching counting was 
performed in parallel to the experiments. Time course and 
number of scratches through injection site via hindpaws 
of mice were counted by an observer during each 10-min 
interval of the entire 30 min observation period, according 
to the previous studies (0–10, 10–20 and 20–30 min) (Andoh 
and Kuraishi 1998, Togashi et al. 2002). 
Different doses morphine (1, 3, 10 mg/kg), tramadol (20, 
40, 80 mg/kg), CP 55,940 (0.1, 0.3, 1 mg/kg), paracetamol 
(100, 200, 300 mg/kg) and diclofenac (50, 100, 200 mg/kg) 
were given i.p. 30 min prior to intradermal pruritogen 
injections. All of drug doses were selected according to 
their antinociceptive doses obtained in various studies for 
morphine, tramadol, CP 55,940, paracetamol and diclofenac; 
respectively (Jin et al. 2014, Aydin et al. 2012, Miller et al. 
2012, Roca-Vinardell et al. 2003, Hossain at al. 2013). Control 
mice received saline (physiologic % 0.9 sodium chloride 
solution) or vehicle solution, were intraperitoneally (i.p.) 
administered. To compare the statistical significance of 
serotonin and compound 48/80 on itch behavor, saline and 
vehicle solution also were given into the neck of mice.
Statistical analysis
All data are expressed as means ±SEMs. Groups of 
6–15 mice were used. The significance of any difference 
was assessed using one-way ANOVA or two-way repeated-
-measures ANOVA followed by the Bonferroni post hoc test. 
Statistical data analysis was performed using Graph Pad 
Prism version 4.0 software (Graph Pad, San Diego, CA).
RESULTS
The effects of analgesic drugs on intradermal 
compound 48/80-induced scratches 
Intradermal 0.9% saline, and vehicle in which 
paracetamol and CP 55,940 were dissolved, injected into the 
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rostral back, elicited a total of 2±0.54 and 1.16±0.57 scratches, 
respectively, in 30 min. Repeated measure of two way ANOVA 
showed that intradermal administration of compound 
48/80 resulted in a significant increase in the number of 
scratches as compared to saline and vehicle treated control 
groups (Figs 11A and 11B). Scratching elicited by compound 
48/80 administrations was significantly increased at 10, 
20 and 30 min compared to saline and vehicle groups, 
(F1,121=38.71, p<0.001) and (F=1.63, p<0.001), respectively. 
Total number of scratches to compound 48/80 (100 µg) 
was found to be 145.15±15.8 within 30 min. Morphine 
dose dependently and significantly blocked the number of 
scratches elicited by compound 48/80 (F3,56=16.97, p<0.001, 
n=7) (Figs 1A and 1B). While there was no significant 
change in the number of scratches when the morphine at 
the dose of 1 mg/kg was administered (148±7.8) (Figs 1A 
and 1B), however a peak effect with the fully resolving of 
scratches was obtained after the morphine at the dose of 
10 mg/kg, (Fig. 1B). Similar to morphine, tramadol also 
dose dependently inhibited compound 48/80 induced 
scratches at 10, 20 and 30 min (F3,48=46.39, p<0.001, n=7) 
(Fig. 2A). The maximal dose of tramadol (80 mg/kg) lead 
to totally inhibition of compound 48/80 induced scratches 
during the 30 min observation period (Fig. 2B). 
The cannabinod drug, CP 55,940 elicited dose dependent 
antiscratching effect at 10, 20 and 30 min after compound 
48/80 administration (F3,40=21.19, p<0.001, n=6) (Fig. 3A). 
While the lowest dose of CP 55,940 (0.1 mg/kg) lead to 67±11 
scratches within 30 min, its highest dose (1 mg/kg) totally 
abolished scratch bouts after compound 48/80 injection 
(Fig. 3B). 
The widely used analgesic drug, paracetamol, 
dose dependently reduced scratches bouts induced by 
compound 48/80 (F3,40=28.14, p<0.001, n=6) (Fig. 4A). The 
total number of scratches within 30 min after compound 
48/80 administration was 4±0.84 following the highest dose 
of paracetamol (300 mg/kg) (Fig. 4B). The NSAID, diclofenac, 
also dose dependenly and significantly blocked compound 
48/80 induced scratches (F3,40=18.42, p<0.001, n=6) (Fig. 5A). 
While the lowest dose of diclofenac (50 mg/kg) was 
ineffective, its highest dose (200 mg/kg) fully inhibited 
scratches elicited by the compound 48/80 within 30 min 
after its injection (Fig. 5B). 
The effects of analgesic drugs on intradermal 
serotonin-induced scratches
Intradermal injection of serotonin into the nape of 
the neck elicited a significant increase in the number 
of scratches at 10, 20 and 30 min after injection when 
compared to saline and vehicle treated control groups (Figs 
Fig. 1. (A) Morphine was given i.p. 30 min prior to intradermal compound 
48–80 injection and the number of bouts of scratching behavior was 
measured between 0–10, 10–20 and 20–30 min after the injection. (B) Total 
number of scratches for 30 min were compared in each morphine dose 
group against control group. *p<0.001, compared to control groups.
Fig. 2. (A) CP 55,940 was given i.p. 30 min prior to intradermal compound 
48–80 injection and the number of bouts of scratching behavior was 
measured between 0–10, 10–20 and 20–30 min after the injection. (B) Total 
number of scratches for 30 min were compared in each CP 55,940 dose 
group against control group. *p<0.001, compared to control groups.
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11A and 11B). Total number of scratches for 30 min after 
serotonin injection was found to be 28.5±1.6 (Figs 11A and 
11B). Morphine dose dependently and significantly blocked 
serotonin induced scratching behavior (F3,40=29.9 p<0.001, 
n=6) (Fig. 6A). At the dose of 10 mg/kg morphine decreased 
serotonin-induced scratches to 0.8±0.4 within 30 min 
(Fig. 6B). Similar to morphine, tramadol dose dependently 
and significantly blocked serotonin induced scratching 
behavior at 10, 20 and 30 min (F3,40=125.5 p<0.001, n=6) 
(Figs 7A and 7B). The highest dose of tramadol (80 mg/kg) 
decreased the serotonin induced scratches from 30.17±2.52 
to 0.5±0.34 within 30 min (Fig. 7B). 
CP 55,940 produced a dose-related antiscratching 
effect at 10, 20 and 30 min after serotonin injection 
(F3,40=75.75, p<0.001, n=6) (Fig. 8A). While the lowest dose 
of CP 55,940 (0.1 mg/kg) elicited 5.5±1.87 scratches, its 
highest dose (1 mg/kg) effectively diminished scratches to 
0.5±0.22 s within 30 min after serotonin injection (Fig. 8B). 
Paracetamol elicited a significant effect on serotonin-
induced scratches (F3,40=7.24, p<0.001, n=6) (Fig. 9A). While 
the lowest dose of paracetamol (100 mg/kg) was ineffective, 
its highest dose (300 mg/kg) blocked scratches at 10 and 
20 min after serotonin injection (Fig. 9B). The highest dose 
of paracetamol (300 mg/kg) decreased serotonin induced 
scratches from 28.5±1.67 to 3.5±1.46 within 30 min (Fig. 9B). 
Diclofenac also dose-dependently and significantly blocked 
serotonin-induced scratching behavior (F3,40=18.42, p<0.001, 
n=6) (Fig. 10A). The lowest dose of diclofenac (50 mg/kg) 
did not alter the number of scratches induced by serotonin, 
whereas its highest dose (200 mg/kg) totally inhibited 
scratches induced by serotonin within 30 min (Fig. 10B). 
DISCUSSION
In this study, we evaluated the effects of 
analgesic drugs on intradermally applied pruritic agents, 
compound 48/80 and serotonin-induced scracthing 
behavior, which suggested the most characteristic response 
to itching in animals. The doses of the analgesic drugs 
used in our study are selected according to their potent 
analgesic effects in various pain models in mice (Jin et al. 
2014, Aydin et al. 2012, Miller et al. 2012, Roca-Vinardell et 
al. 2003, Hossain at al. 2013). Our observation showed that 
all of the analgesic drugs effectively blocked intradermal 
pruritogen-induced scratches when applied into the nape 
of the neck of mice.
Most of the previous studies performed on the basis 
of application of the some pruritive substances into the 
neck of rodents (Kuraishi et al. 1995, Inagaki et al. 2002, 
Green et al. 2006, Shimada et al. 2006). While serotonin 
acts as a neurotransmitter in the central nervous system 
Fig. 3. (A) Tramadol was given i.p. 30 min prior to intradermal compound 
48–80 injection and the number of bouts of scratching behavior was 
measured between 0–10, 10–20 and 20–30 min after the injection. (B) Total 
number of scratches for 30 min were compared in each tramadol dose 
group against control group. *p<0.001, compared to control groups.
Fig. 4. (A) Paracetamol was given i.p. 30 min prior to intradermal compound 
48–80 injection and the number of bouts of scratching behavior was 
measured between 0–10, 10–20 and 20–30 min after the injection. (B) Total 
number of scratches for 30 min were compared in each paracetamol dose 
group against control group. *p<0.001, compared to control groups.
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(Budzinska et al. 2014), it elicits a clear itch when applied 
in rodents peripherally (Yamaguchi et al. 1999, Jinks and 
Carstens 2002). Also, compound 48/80 is a well known mast 
cell degranulator agent and causes itch via liberation of 
histamine, furthermore it was reported that the pruritic 
effect compound 48/80 occurs via mast cell-independent 
pathway (Inagaki et al. 2002). However, currently it should 
be questioned that how much these agents lead to real 
itch behavior when applied into the neck of rodents. 
According to our results, all of analgesic drugs used in our 
study completely blocked scratching. Thus, we should face 
whether the application of the putative pruritogens may 
cause real pain rather than pruritus and than analgesics 
really block pain.
Some previous studies have proposed that substances 
induce scratching behavior in some situation may reflect 
pain rather than itch in humans depending on the 
application of the site. For example, capsaicin has been 
shown to produce itch when applied in a punctiform 
manner into the skin (Sikand et al. 2009). Additionally, it 
was indicated that when capsaicin was applied topically, it 
caused itch more than pain (Green 1990, Wang et al. 2010). 
On the contrary, it has also been reported that intradermal 
injections of capsaicin casuses pain by leading burning or 
stinging (Byas-Smith et al. 1999, Simone et al. 1989). For 
this reason, to differentiate the pain and itch behavior by 
applying the putative pruritogens in animals, Shimada and 
LaMotte (2008) proposed mouse cheek model, with hind 
limb scratches and forelimb wiping behavior. According to 
the results performed by Shimada and LaMotte (2008), both 
histamine and capsaicin caused scratching behaviour when 
applied into the nape of neck and one type of behaviour was 
only seen described as hind limb scratching (Shimada and 
LaMotte 2008). However, in the cheek models, capsaicin have 
been shown to cause wiping when applied into the cheek, 
rather than itching, as an indicator of pain. Akiyama and 
others (2010) reported that systemically applied morphine 
couldn’t inhibit intradermal serotonin and histamine 
induced itch when applied to the cheek, and morphine 
has been shown to reduce wiping caused by capsaicin. For 
this reason, some authors have adviced that wiping and 
scratching are distinguished in relation to the inhibition 
of the effects of the putative algesiogenic capsaicin and 
putative pruritogens histamine and serotonin, so wiping 
shows pain, and scratching shows itch, in cheek model 
(Shimada and LaMotte 2008, Akiyama et al. 2010). Morever, 
intracisternal application morphine has been shown to 
potentiate the intradermally injected serotonin induced 
scratch in eye-wiping test in rats (Moser and Giesler 2014). 
Clinically opioid induced itch was well reported in many 
studies as an adverse effect (Cousins and Mather 1984, 
Ballantyne et al. 1988). Opioid antagonists, mainly naloxone 
Fig. 5. (A) Diclofenac was given i.p. 30 min prior to intradermal compound 
48–80 injection and the number of bouts of scratching behavior was 
measured between 0–10, 10–20 and 20–30 min after the injection. (B) Total 
number of scratches for 30 min were compared in each diclofenac dose 
group against control group. *p<0.001, compared to control groups.
Fig. 6. (A) Morphine was given i.p. 30 min prior to intradermal serotonin 
injection and the number of bouts of scratching behavior was measured 
between 0–10, 10–20 and 20–30 min after the injection. (B) Total number 
of scratches for 30 min were compared in each morphine dose group 
against control group. *p<0.001, compared to control groups.
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is used in the treatment of opioid-induced itch (Bergasa et 
al. 1995, Brune et al. 2004). However, in our study, morphine 
(at the dose of 3 and 10 mg/kg, i.p.) and tramadol, and 
also other analgesics, clearly diminished the serotonin 
and compound 48/80 induced scrathes when applied 
into the neck in a dose dependent manner. Morphine at 
the dose of 10 mg/kg, i.p. may be sedative, however dose 
of 3 mg/kg, i.p. is not sedative (Patti et al. 2005) and give 
similiar significance comparated to the dose of 10 mg/kg, 
i.p. used in our study. These results may support our claim, 
the lack of effect of morphine on scratching in cheek 
model performed by Akiyama et al. shows that putative 
pruritogens lead to more itch behaviour in cheek model in 
comparation to the neck model. Furthermore, scratching 
behavior in arthritic rats induced by inoculation with 
mycobacterium butyricum was inhibited by morphine and 
acetylsalicylate, suggesting that the scratching reflected 
pain rather than itch (De Castro-Costa et al. 1987). 
In addition to their analgesic effect, in certain human 
studies it was shown that cannabinoids were effective in 
the treatment of pruritus, i.e. cholestatic pruritus (Neff et 
al. 2002) and the synthetic cannabinoid agonist HU-211 
also supressed pruritus when applied locally (Dvorak et 
al. 2003). In experimental studies, it was reported that 
an exogeneous cannabinoid Δ (9)-tetrahydrocannabinol 
and fatty acid amide hydrolase (FAAH) enzyme inhibitor 
URB597 reduced the itching behavior induced by compound 
48/80 (Schlosburg et al. 2009). Furthermore, S-777469, 
a novel cannabinoid type 2 receptor agonist, in mice has 
been shown to reduce the scratches (Haruna et al. 2016). 
These findings support the antipruritic effect of various 
cannabinoidergic drugs or substances depends on the neck 
model (Haruna et al. 2016, Schlosburg et al. 2009). However, 
Spradley and others (2012) proposed that the inhibition 
of 5-HT induced scratching in the rostral back (but not in 
the cheek) by the previously administration of degrading 
enzymes for the endocannabinoids anandamide (URB597) 
or 2-arachidonoylglycerol (JZL184) may depend the 
differences of the pain and itch arising from trigeminally-
innervated skin of the face or scalp. This finding elicited 
by the Spradley and others (2012) supports our finding 
that the cannabinoid receptor agonist CP 55,940 inhibited 
itch responses in neck model with all the doses used. 
Nonetheless, we don’t fully claim that cannabinoidergic 
drugs don’t exert any antipruritic effect, further studies 
must be performed via using both neck and cheek models 
to research the exact mechanism of the cannabinoidergic 
susbtances for itch.
It was shown that itch is blocked by certain NSAIDs 
such as tenoxicam and diclofenac, in humans (Colbert et al. 
1999, Chang et al. 2013). The effect of prostaglandins (PGs) 
on pruritus has also been researched in further studies 
Fig. 7. (A) CP 55,940 was given i.p. 30 min prior to intradermal serotonin 
injection and the number of bouts of scratching behavior was measured 
between 0–10, 10–20 and 20–30 min after the injection. (B) Total number 
of scratches for 30 min were compared in each CP 55,940 dose group 
against control group. *p<0.001, compared to control groups.
Fig. 8. (A) Tramadol was given i.p. 30 min prior to intradermal serotonin 
injection and the number of bouts of scratching behavior was measured 
between 0–10, 10–20 and 20–30 min after the injection. (B) Total number 
of scratches for 30 min were compared in each tramadol dose group 
against control group. *p<0.001, compared to control groups.
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including both human (Neisius et al. 2002) and rodents 
(Andoh and Kuraishi 1998, Takaoka et al. 2007). The 
importance of the arachidonic acid cascade in substance 
P-induced itch and the inhibition of the production of 
leukotriene B4 for the inhibitory effect of dexamethasone 
on itch-associated response has been pointed out (Andoh 
and Kuraishi 1998). Histamine release from mast cells 
induced by fibrinogen degradation product was reversed 
by anti-inflammatory drugs (Wojtecka-Lukasik et al. 1988). 
Thus, blocking the certain mediators by the analgesic 
NSAIDs may support the inhibition of itch. However, these 
experimental studies research the role of prostaglandins 
depend also neck models (Andoh and Kuraishi 1998, 
Takaoka et al. 2007). In our study, potent and weak 
PG synthesis inhibitors diclofenac and paracetamol, 
respectively, inhibited the scratching behavior. Our finding 
suggest that NSAIDs may inhibit pain behavior rather than 
itch. Further studies must be done to differentiate pain 
and itch behavior by using cheek cheek and neck models. 
Despite this, also in neck models some conflicting results 
have been declared regarding the effect of certain types of 
NSAIDs on itch behavior. For instance, Andoh and Kuraishi 
(1998) showed that NSAIDs indomethacin and diclofenac 
have been shown to exert no effect on substance P-induced 
scratching in mice in neck model. This discrepancy may 
arise from the different pruritogen used (substance-P) or 
pharmacokinetic profile or both. In that study, the dose of 
diclofenac and indomethacin were 3–10 and 1–10 mg/kg, 
respectively and were given by peroral route. However, 
in our study diclofenac was administered at the dose of 
50–200 mg/kg, i.p. Moreover, indomethacin has been 
shown to have no effect on scratching behavior induced 
by compound 48/80 in neck model (Inagaki et al. 2002). 
In that study, indomethacin was also given at the dose of 
1–10 mg/kg, but we don’t think this effect has most likely 
arised from pharmacokinetic profile, because the dose 
10 mg/kg of indomethacin is an analgesic dose used in most 
of the pain studies (Lavich et al. 2005, Zhao et al. 2014). In 
our study, also the low dose of indomethacin; 50 mg/kg, 
i.p., exerted a significant reduction on scratching behavior 
at the 30th minute. Thus, the lack of effect of indomethacin 
may be clarified by further studies. Taken together, the 
inhibitor effect of diclofenac and paracetamol may depend 
on their pain reducing effects.
Regarding the close interaction between pain and itch, 
the phenomena of allokinesis has been described (Simone 
et al. 1991, Heyer et al. 1995). As seen in the mechanism 
of allodynia development (Ran et al. 2014) persistent 
stimulation of primary afferents (pruritis receptors), 
causes allokinesis explained on the basis of central 
Fig. 9. (A) Paracetamol was given i.p. 30 min prior to intradermal serotonin 
injection and the number of bouts of scratching behavior was measured 
between 0–10, 10–20 and 20–30 min after the injection. (B) Total number 
of scratches for 30 min were compared in each paracetamol dose group 
against control group. *p<0.001, compared to control groups.
Fig. 10. (A) Diclofenac was given i.p. 30 min prior to intradermal serotonin 
48–80 injection and the number of bouts of scratching behavior was 
measured between 0–10, 10–20 and 20–30 min after the injection. (B) Total 
number of scratches for 30 min were compared in each diclofenac dose 
group against control group. *p<0.001, compared to control groups.
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sensitization in chronic itch and elicited by low-threshold 
mechanoreceptors, Aβ fibers induced by touching. In this 
phenomena, a normal touching that does not lead to any 
itching behavior, however, leads to itching in the patient 
whom allokinesis developed. Furthermore, application 
of pinprick causes itch sensations in the surroundings of 
itching skin areas, though normally pinprick is a painful 
stimuli, also called hyperkinesis, have been reported 
following histamine iontophoresis in healthy volunteers 
(Atanassoff et al. 1999). In hyperkinesis, it has also been 
suggested that normally painful electrical stimuli were 
perceived as itching in the patients with atopic dermatitis 
(Nilsson and Schouenborg 1999). According to our data, 
we claim that the antipruritic effect of analgesic drugs 
might have been less likely arised from the phenomena 
of allokinesis or hyperkinesis because of the evaluating 
the acute situations. It is well known that both allokinesis 
and hyperkinesis are the phenomena seen in the chronic 
processes, such as atopic dermatitis (Heyer et al. 1995, 
Groene et al. 2001). For instance in the study performed 
by Groene and others (2001), intradermally injected of 
acetylcholine, which normally provokes pain, provokes 
itch in patients with atopic dermatitis. Thus, it was 
suggested that in patients with chronic itch, a stimuli 
normally cause pain may be perceived as itch according 
to the central processing of pruritus. However, in our 
study we didn’t mimic the chronic itch models such as 
atopic dermatitis in rats and we have not claimed that 
the blocking itch behaviour effect of antinociceptive 
agents used in our study might have been arised from the 
phenomena of allokinesis.
Despite the potential separative effect of cheek 
model, also some uncertainties are seen in this model. 
For example, interestingly, in the cheek model, Gomes et 
al. suggested that endothelin-1 (ET-1) produces both pain 
and itch and the scratch and pain behaviours can not be 
distinguished (Gomes et al. 2012). This finding shows that 
itch and pain behavior may also alter according to the 
applied chemical agent as well as the application site. For 
example, morphine and the other analgesics used in our 
study completely blocked the pruritic effect of compound 
48/80 and serotonin, which are putative pruritogenic 
agents. However, in one study, Liang et al., proposed that 
ET-1 induced scratching behavior was not blocked by 
systemically applied morphine in the neck model (Liang et 
al. 2011). This finding may arise from the administration 
of a different route, a different pruritogen (ET-1) or 
the relatively low dose of subcutaneously (s.c.) applied 
morphine, 1 mg/kg, s.c., similarly, in our study while the 
1 mg/kg, i.p. dose of morphine couldn’t reduce the effect 
of compound 48/80 induced scratching, the higher doses 
were significantly effective. According to these findings, 
we suggest that putative pruritic effect may also depend on 
the type of the chemical, in this regard. As a result, the neck 
model may give false positive results, however, as discussed 
before, the lack of effect of morphine on ET-1 (even may 
arise from the low dose) in the neck model shows that 
there is no perfect itch model that separate pain and itch 
behavior well, it may change according to the applied 
pruritogens and the application site.
As proposed above, the difference between the itch 
and pain may also arise from the applied cite. Kuraishi 
and others (1995) suggested that compound 48/80 and 
substance P, but not capsaicin and histamine, caused 
pruritus when given by subcutaneous route in mice. 
In that study, we propose that the ineffectiveness of 
capsaicin and histamine on itch behavior may be arised 
from the different injection site, because Kuraishi et al. 
applied these agents subcutaneously, not intradermally 
to the neck. This finding shows that itch behavior 
induced by putative pruritogens may alter according 
to the different application site, such as surface of skin 
(topical), intradermal and subcutaneous. Currently, to 
differentiate pain and itch receptors, it has been shown 
that MrcprA3 receptors are specifically responsible from 
itch transmission. According to the study performed by 
Han and others (2013), when mice TRPV1 receptors in 
MrgprA3(+) expressing neurons were excited by injection 
of capsaicin, a well-established mediator thought to be 
Fig. 11. (A) Intraperitoneal administered saline was given i.p. 30 min prior 
to intradermal saline, vehicle, serotonin and compound 48/80, and the 
number of bouts of scratching behavior was measured between 0–10, 
10–20 and 20–30 min after the injection. (B) Total number of scratches 
for 30 min were compared in each saline (i.p.) group against control 
group. *p<0.001, compared to control groups (intradermally injected 
saline and vehicle).
Note that all control groups are the pruritogens given only alone.
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algesiogenic, the mice exerted itch behavior rather than 
pain. This finding support that pruritogens are criticism 
of itch models, chemicals which may not be always 
spesific to itch behavior and may be variable according to 
the application site even induced by the same pruritogen.
In conclusion, establishing a better model of itch is 
urgently needed. In the current models, intradermal 
application of the pruritogens into the rostral part of 
the neck may not ideal model for itch and may give false 
positive results with analgesic drugs, hence we claim that 
the neck model is inefficient for the pure determination of 
pain and itch for the drug effects on itch and pain. Because 
of the similarities and differences between pain and itch, we 
believe that new animal itch models have to be established 
to evaluate the real potency of the drugs used for anti-itch 
therapy. At least, currently, both neck and cheek models 
may be used in a comparative manner.
ACKNOWLEDGMENT 
This research was performed in the laboratories of 
Ondokuz Mayıs University, School of Medicine, Department 
of Pharmacology, Samsun/Turkey and Department of 
Dermatology, Gülhane School of Medicine, Gülhane Military 
Medical Academy, Ankara, Turkey.
REFERENCES
Akiyama T, Carstens MI, Carstens E (2010) Differential itch- and pain-related 
behavioral responses and micro-opoid modulation in mice. Acta Derm 
Venereol 90(6): 575–581.
Andoh T, Kuraishi Y (1998) Intradermal leukotriene B4, but not 
prostaglandin E2, induces itch-associated responses in mice. Eur J 
Pharmacol 353(1): 93–96.
Atanassoff PG, Brull SJ, Zhang J, Greenquist K, Silverman DG, Lamotte RH 
(1999) Enhancement of experimental pruritus and mechanically evoked 
dysesthesiae with local anesthesia. Somatosens Mot Res 16(4): 291–298.
Aydin ON, Ek RO, Temoçin S, Uğur B, Alaçam B, Şen S (2012) The 
antinociceptive effects of systemic administration of tramadol, 
gabapentin and their combination on mice model of acute pain. Agri 
24(2): 49–55.
Ballantyne JC, Loach AB, Carr DB (1988) Itching after epidural and spinal 
opiates. Pain 33(2): 149–160.
Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, 
Schmitt JM, Walker EC, Jones EA (1995) Effects of naloxone infusions in 
patients with the pruritus of cholestasis. A double-blind, randomized, 
controlled trial. Ann Intern Med 123(3): 161–167.
Brune A, Metze D, Luger TA, Ständer S (2004) Antipruritic therapy with 
the oral opioid receptor antagonist naltrexone. Open, non-placebo 
controlled administration in 133 patients. Hautarzt 55(12): 1130–1136.
Budzinska K, Andrzejewski K (2014) Respiratory activity in the 
6-hydroxydopamine model of Parkinson’s disease in the rat. Acta 
Neurobiol Exp (Wars) 74(1): 67–81.
Byas-Smith MG, Bennett GJ, Gracely RH, Max MB, Robinovitz E, Dubner R 
(1999) Tourniquet constriction exacerbates hyperalgesia-related pain 
induced by intradermal capsaicin injection. Anesthesiology 91(3): 617–625.
Carstens E, Akiyama T (2014) Itch: Mechanisms and Treatment. Frontiers in 
Neuroscience. Boca Raton CRC Press/Taylor & Francis, London–New York.
Chang WK, Wu HL, Yang CS, Chang KY, Liu CL, Chan KH, Sung CS (2013) 
Effect on pain relief and inflammatory response following addition of 
tenoxicam to intravenous patient-controlled morphine analgesia: a 
double-blind, randomized, controlled study in patients undergoing 
spine fusion surgery. Pain Med 14(5): 736–748.
Colbert S, O’Hanlon DM, Galvin S, Chambers F, Moriarty DC (1999) The 
effect of rectal diclofenac on pruritus in patients receiving intrathecal 
morphine. Anaesthesia 54(10): 948–952.
Cousins MJ, Mather LE (1984) Intrathecal and epidural administration of 
opioids. Anesthesiology 61(3): 276–310.
Davidson S, Giesler GJ (2010) The multiple pathways for itch and their 
interactions with pain. Trends Neurosci 33(12): 550–558.
De Castro-Costa M, Gybels J, Kupers R, Van Hees J (1987) Scratching 
behaviour in arthritic rats: a sign of chronic pain or itch?. Pain 29(1): 
123–131.
Denayer T, Stöhrn T, Van Roy M (2014) Animal models in translational 
medicine: Validation and prediction. New Horiz Transl Med 2(1): 5–11.
Dvorak M, Watkinson A, McGlone F, Rukwied R (2003) Histamine induced 
responses are attenuated by a cannabinoid receptor agonist in human 
skin. Inflamm Res 52(6): 238–245.
Gobira PH, Ropke J, Aguiar DC, Crippa JA, Moreira FA (2013) Animal models 
for predicting the efficacy and side effects of antipsychotic drugs. Rev 
Bras Psiquiatr 35 Suppl 2: S132–S139.
Gomes LO, Hara DB, Rae GA (2012) Endothelin-1 induces itch and pain in 
the mouse cheek model. Life Sci 91(13–14): 628–633.
Green AD, Young KK, Lehto SG, Smith SB, Mogil JS (2006) Influence of 
genotype, dose and sex on pruritogen-induced scratching behavior in 
the mouse. Pain 124(1–2): 50–58.
Green BG (1990) Spatial summation of chemical irritation and itch 
produced by topical application of capsaicin. Percept Psychophys 48(1): 
12–18.
Groene D, Martus P, Heyer G (2001) Doxepin affects acetylcholine induced 
cutaneous reactions in atopic eczema. Exp Dermatol 10(2): 10–117.
Hachisuka J, Ross SE (2014) Understanding the switch from pain-to-itch in 
dermatitis. Neurosci Lett 579: 188–189.
Han L, Dong X (2014) Itch mechanisms and circuits. Annu Rev Biophys 43: 
331–355.
Han L, Ma C, Liu Q, Weng HJ, Cui Y, Tang Z, Kim Y, Nie H, Qu L, Patel 
KN, Li Z, McNeil B, He S, Guan Y, Xiao B, Lamotte RH, Dong X (2013) 
A subpopulation of nociceptors specifically linked to itch. Nat Neurosci 
16: 174–182.
Haruna T, Soga M, Morioka Y, Hikita I, Imura K, Furue Y, Yamamoto M, 
Imura C, Ikeda M, Yamauchi A, Deguchi M, Shichijo M, Arimura A, 
Yasui K (2016) S-777469, a novel cannabinoid type 2 receptor agonist, 
suppresses itch-associated scratching behavior in rodents through 
inhibition of itch signal transmission. Pharmacology 95: 95–103.
Heyer G, Ulmer FJ, Schmitz J, Handwerker HO (1995) Histamine-induced 
itch and alloknesis (itchy skin) in atopic eczema patients and controls. 
Acta Derm Venereol 75(5): 348–352.
Hossain H, Jahan IA, Islam HS, Kanti DS, Arpona H, Arif A (2013) Phytochemical 
screening and anti-nociceptive properties of the ethanolic leaf extract of 
trema cannabina lour. Adv Pharm Bull 3(1): 103–108.
Inagaki N, Igeta K, Kim JF, Nagao M, Shiraishi N, Nakamura N, Nagai H 
(2002) Involvement of unique mechanisms in the induction of scratching 
behavior in BALB/c mice by compound 48/80. Eur J Pharmacol 448(2–3): 
175–183.
Jin L, Pan L, Guo Y, Zheng Y, Nie Z, Zhu R (2014) Expression and localization 
of cannabinoid receptor 1 in rats’ brain treated with acute and repeated 
morphine. Acta Neurobiol Exp (Wars) 74(3): 288–297.
Jinks S, Carstens E (2002) Responses of superficial dorsal horn neurons to 
intradermal serotonin and other irritants: comparison with scratching 
behavior. J Neurophysiol 87 (3): 1280–1289.
8_769_Ilkaya_v4.indd   242 08/09/16   21:29
Acta Neurobiol Exp 2016, 76: 234–243 Analgesic drugs decrease itching behavior in mice 243
Kremer AE, Martens JJ, Kulik W, Ruëff F, Kuiper EM, van Buuren HR, van 
Erpecum KJ, Kondrackiene J, Prieto J, Rust C, Geenes VL, Williamson C, 
Moolenaar WH, Beuers U, Oude Elferink RP (2010) Lysophosphatidic 
acid is a potential mediator of cholestatic pruritus. Gastroenterology 
139(3): 1008–1018.
Kuraishi Y, Nagasawa T, Hayashi K, Satoh M (1995) Scratching behavior 
induced by pruritogenic but not algesiogenic agents in mice. Eur J 
Pharmacol 275(3): 229–233.
LaMotte RH, Shimada SG, Sikand P (2011) Mouse models of acute, chemical 
itch and pain in humans. Exp Dermatol 20(10): 778–782.
Lavich TR, Cordeiro RS, Silva PM, Martins MA (2005) A novel hot-plate test 
sensitive to hyperalgesic stimuli and non-opioid analgesics. Braz J Med 
Biol Res 38(3): 445–451.
Liang J, Ji Q, Ji W (2011) Role of transient receptor potential ankyrin 
subfamily member 1 in pruritus induced by endothelin-1. Neurosci Lett 
492(3): 175–178.
Miller LL, Picker MJ, Umberger MD, Schmidt KT, Dykstra LA (2012) Effects 
of alterations in cannabinoid signaling, alone and in combination with 
morphine, on pain-elicited and pain-suppressed behavior in mice. 
J Pharmacol Exp Ther 342(1): 177–187.
Moser HR, Giesler GJ Jr (2014) Itch elicited by intradermal injection of 
serotonin, intracisternal injection of morphine, and their synergistic 
interactions in rats. Neuroscience 274: 119–127.
Neff GW, O’Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, Amaro R, 
Rodriguez MJ, Chase V, Jeffers L, Schiff E (2002) Preliminary observation 
with dronabinol in patients with intractable pruritus secondary to 
cholestatic liver disease. Am J Gastroenterol 97(8): 2117–2119.
Neisius U, Olsson R, Rukwied R, Lischetzki G, Schmelz M (2002) 
Prostaglandin E2 induces vasodilation and pruritus, but no protein 
extravasation in atopic dermatitis and controls. J Am Acad Dermatol 
47(1): 28–32.
Nilsson HJ, Schouenborg J (1999) Differential inhibitory effect on human 
nociceptive skin senses induced by local stimulation of thin cutaneous 
fibers. Pain 80(1–2): 103–112.
Patti CL, Frussa-Filho R, Silva RH, Carvalho RC, Kameda SR, Takatsu-
-Coleman AL, Cunha JL, Abílio VC (2005) Behavioral characterization of 
morphine effects on motor activity in mice. Pharmacol Biochem Behav 
81(4): 923–927.
Paus R, Schmelz M, Bíró T, Steinhoff M (2006) Frontiers in pruritus research: 
scratching the brain for more effective itch therapy. J Clin Invest 116(5): 
1174–1186.
Ran R, Gu J, Fu J, Zhong H, Zhao Y, Gu Y, Zhang A, Li G, Wang L, Wang Q 
(2014) The role of the GABA-A receptor of the adjacent intact dorsal 
root ganglion neurons in rats with neuropathic pain. Acta Neurobiol Exp 
(Wars) 74(4): 405–414.
Ringkamp M, Meyer R (2014) Pruriceptors. In: Itch: Mechanisms and 
Treatment. Frontiers in Neuroscience (Carstens E, Akiyama T, Eds.). 
Boca Raton CRC Press/Taylor & Francis, London–New York.
Roca-Vinardell A, Ortega-Alvaro A, Gibert-Rahola J, Micó JA (2003) The role 
of 5-HT1A/B autoreceptors in the antinociceptive effect of systemic 
administration of acetaminophen. Anesthesiology 98(3): 741–747.
Schlosburg JE, Boger DL, Cravatt BF, Lichtman AH (2009) Endocannabinoid 
modulation of scratching response in an acute allergenic model: a new 
prospective neural therapeutic target for pruritus. J Pharmacol Exp Ther 
329(1): 314–323.
Shimada SG LaMotte RH (2008) Behavioral differentiation between itch 
and pain in mouse. Pain 139(3): 681–687.
Shimada SG, Shimada KA, Collins JG (2006) Scratching behavior in mice 
induced by the proteinase-activated receptor-2 agonist, SLIGRL-NH2. 
Eur J Pharmacol 530(3): 281–283.
Sikand P, Shimada SG, Green BG, LaMotte RH (2009) Similar itch and 
nociceptive sensations evoked by punctate cutaneous application of 
capsaicin, histamine and cowhage. Pain 144(1–2): 66–75.
Simone DA, Alreja M, LaMotte RH (1991) Psychophysical studies of the 
itch sensation and itchy skin (“alloknesis”) produced by intracutaneous 
injection of histamine. Somatosens Mot Res 8(3): 271–279.
Simone DA, Baumann TK, LaMotte RH (1989) Dose-dependent pain and 
mechanical hyperalgesia in humans after intradermal injection of 
capsaicin. Pain 38(1): 99–107.
Spradley JM, Davoodi A, Gee LB, Carstens MI, Carstens E (2012) Differences 
in peripheral endocannabinoid modulation of scratching behavior in 
facial vs. spinally-innervated skin. Neuropharmacology 63(4): 743–749.
Takaoka A, Arai I, Sugimoto M, Futaki N, Sakurai T, Honma Y, Nakaike S 
(2007) Role of scratch-induced cutaneous prostaglandin D production on 
atopic-like scratching behaviour in mice. Exp Dermatol 16(4): 331–339.
Togashi Y, Umeuchi H, Okano K, Ando N, Yoshizawa Y, Honda T, 
Kawamura  K, Endoh T, Utsumi J, Kamei J, Tanaka T, Nagase H (2002) 
Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J 
Pharmacol 435(2–3): 259–264.
Wang H, Papoiu AD, Coghill RC, Patel T, Wang N, Yosipovitch G (2010) Ethnic 
differences in pain, itch and thermal detection in response to topical 
capsaicin: African Americans display a notably limited hyperalgesia and 
neurogenic inflammation. Br J Dermatol 162(5): 1023–1029.
Wojtecka-Lukasik E, Stachurska J, Kopeć M, Maśliński S (1988) Anti-
-inflammatory drugs modulate histamine release from mast cells induced 
by fibrinogen degradation products. Ann Rheum Dis 47(4): 328–332.
Yamaguchi T, Nagasawa T, Satoh M, Kuraishi Y (1999) Itch associated 
response induced by intradermal serotonin through 5-HT2 receptors in 
mice. Neurosci Res 35(2): 77–83.
Zachariae R, Lei U, Haedersdal M, Zachariae C (2012) Itch severity and 
quality of life in patients with pruritus: preliminary validity of a Danish 
adaptation of the itch severity scale. Acta Derm Venereol 92(5): 508–514.
Zhao H, Luo F, Li H, Zhang L, Yi Y, Wan J (2014) Antinociceptive effect of 
tetrandrine on LPS-induced hyperalgesia via the inhibition of IKKbeta 
phosphorylation and the COX-2/PGE(2) pathway in mice. PLoS One 
9(4): e94586.
8_769_Ilkaya_v4.indd   243 08/09/16   21:29
